267 related articles for article (PubMed ID: 14694991)
1. Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients.
Dragovic G; Jevtovic D
Antivir Chem Chemother; 2003 Sep; 14(5):281-4. PubMed ID: 14694991
[TBL] [Abstract][Full Text] [Related]
2. The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients.
Dragovic G; Jevtovic D
Biomed Pharmacother; 2012 Jun; 66(4):308-11. PubMed ID: 22658063
[TBL] [Abstract][Full Text] [Related]
3. Peripheral neuropathy during stavudine-didanosine antiretroviral therapy.
Reliquet V; Mussini JM; Chennebault JM; Lafeuillade A; Raffi F
HIV Med; 2001 Apr; 2(2):92-6. PubMed ID: 11737385
[TBL] [Abstract][Full Text] [Related]
4. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
Moore RD; Keruly JC; Chaisson RE
AIDS; 2001 Mar; 15(5):617-20. PubMed ID: 11316999
[TBL] [Abstract][Full Text] [Related]
5. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
Moore RD; Wong WM; Keruly JC; McArthur JC
AIDS; 2000 Feb; 14(3):273-8. PubMed ID: 10716503
[TBL] [Abstract][Full Text] [Related]
6. The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.
Arenas-Pinto A; Bhaskaran K; Dunn D; Weller IV
Antivir Ther; 2008; 13(2):289-95. PubMed ID: 18505180
[TBL] [Abstract][Full Text] [Related]
7. Incidence of acute pancreatitis and nucleoside reverse transcriptase inhibitors usage.
Dragovic G; Milic N; Jevtovic DJ
Int J STD AIDS; 2005 Jun; 16(6):427-9. PubMed ID: 15969777
[TBL] [Abstract][Full Text] [Related]
8. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy.
Kallianpur AR; Hulgan T; Canter JA; Ritchie MD; Haines JL; Robbins GK; Shafer RW; Clifford DB; Haas DW
AIDS; 2006 Jul; 20(11):1503-13. PubMed ID: 16847405
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial.
Kiwuwa-Muyingo S; Kikaire B; Mambule I; Musana H; Musoro G; Gilks CF; Levin JB; Walker AS
AIDS; 2014 Nov; 28(17):2579-88. PubMed ID: 25574960
[TBL] [Abstract][Full Text] [Related]
11. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study.
Smith CJ; Olsen CH; Mocroft A; Viard JP; Staszewski S; Panos G; Staub T; Blaxhult A; Vetter N; Lundgren JD
AIDS; 2008 Jan; 22(1):47-56. PubMed ID: 18090391
[TBL] [Abstract][Full Text] [Related]
12. Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy.
Clumeck N
Antivir Ther; 1998; 3 Suppl 4():39-43. PubMed ID: 10723508
[TBL] [Abstract][Full Text] [Related]
13. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
Mallal SA; John M; Moore CB; James IR; McKinnon EJ
AIDS; 2000 Jul; 14(10):1309-16. PubMed ID: 10930144
[TBL] [Abstract][Full Text] [Related]
14. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.
Schweinsburg BC; Taylor MJ; Alhassoon OM; Gonzalez R; Brown GG; Ellis RJ; Letendre S; Videen JS; McCutchan JA; Patterson TL; Grant I;
J Neurovirol; 2005 Aug; 11(4):356-64. PubMed ID: 16206458
[TBL] [Abstract][Full Text] [Related]
15. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
16. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management.
Moyle GJ; Sadler M
Drug Saf; 1998 Dec; 19(6):481-94. PubMed ID: 9880091
[TBL] [Abstract][Full Text] [Related]
17. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.
Van Dyke RB; Wang L; Williams PL;
J Infect Dis; 2008 Dec; 198(11):1599-608. PubMed ID: 19000014
[TBL] [Abstract][Full Text] [Related]
18. New questions about an old combination--ddI + d4T.
Proj Inf Perspect; 2003 Jan; (35):13-4. PubMed ID: 12647675
[TBL] [Abstract][Full Text] [Related]
19. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy.
Lewis W
Antivir Ther; 2005; 10 Suppl 2():M13-27. PubMed ID: 16152703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
